No Cover Image

Journal article 904 views 122 downloads

A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression

Amy Romijn Orcid Logo, Julia J Rucklidge, Roeline G Kuijer, Chris Frampton

Australian & New Zealand Journal of Psychiatry, Volume: 51, Issue: 8, Pages: 810 - 821

Swansea University Author: Amy Romijn Orcid Logo

Check full text

DOI (Published version): 10.1177/0004867416686694

Abstract

Objectives: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood...

Full description

Published in: Australian & New Zealand Journal of Psychiatry
ISSN: 0004-8674 1440-1614
Published: 2017
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa40734
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Objectives: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood markers, would predict or impact treatment response. Method: Seventy-nine participants (10 dropouts) not currently taking psychotropic medications with at least moderate scores on self-report mood measures were randomly allocated to receive either a probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum) or a matched placebo, in a double-blind trial for 8 weeks. Data were analysed as intent-to-treat. Results: No significant difference was found between the probiotic and placebo groups on any psychological outcome measure (Cohen's d range = 0.07-0.16) or any blood-based biomarker. At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the Montgomery-Åsberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group ([Formula: see text], p = ns). Baseline vitamin D level was found to moderate treatment effect on several outcome measures. Dry mouth and sleep disruption were reported more frequently in the placebo group. Conclusions: This study found no evidence that the probiotic formulation is effective in treating low mood, or in moderating the levels of inflammatory and other biomarkers. The lack of observed effect on mood symptoms may be due to the severity, chronicity or treatment resistance of the sample; recruiting an antidepressant-naive sample experiencing mild, acute symptoms of low mood, may well yield a different result. Future studies taking a preventative approach or using probiotics as an adjuvant treatment may also be more effective. Vitamin D levels should be monitored in future studies in the area. The results of this trial are preliminary; future studies in the area should not be discouraged.
Keywords: Gut microbiome; depression; probiotics; vitamin D; inflammation
College: Faculty of Medicine, Health and Life Sciences
Issue: 8
Start Page: 810
End Page: 821

Similar Items